Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-08-30
2011-08-30
Spector, Lorraine (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S021200, C530S350000
Reexamination Certificate
active
08008261
ABSTRACT:
This document provides to methods and materials related to apoptosis. For example, methods and materials for modulating apoptosis are provided. In addition, methods and materials for treating a mammal having an apoptosis-associated condition are provided.
REFERENCES:
patent: 4036945 (1977-07-01), Haber
patent: 4331647 (1982-05-01), Goldenberg
patent: 5763223 (1998-06-01), Wiley et al.
patent: 6284236 (2001-09-01), Wiley et al.
patent: 6521228 (2003-02-01), Wiley et al.
patent: 7736637 (2010-06-01), Wiley et al.
patent: 2002/0061525 (2002-05-01), Yelin et al.
patent: 1666591 (2006-06-01), None
patent: WO9111465 (1991-08-01), None
patent: WO2004047871 (2004-06-01), None
Shah et al., In vivo imaging of S-TRAIL-mediated tumor regression and apoptosis, Mol. Ther. 11(6):926-931, Jun. 2005.
Locksley et al., The TNF and TNF receptor superfamilies: Integrating mammalian biology, Cell, 104:487-501, Feb. 23, 2001.
Yan et al., Two-amino acid molecular switch in an epithelial morphogen that regulates binding to tow distinct receptors, Science, 290(5491):523-527, Oct. 20, 2000.
T.E. Creighton, PROTEINS: Structurs and Molecular Principles, (W.H. Freeman & Co.:New York), pp. 223-227, 1984.
GenBank® accession No. NM—001101 dated Nov. 1, 2009.
GenBank® GI No. 112820323 dated Dec. 31, 2006, Accession DQ848564.
Almasan and Ashkenazi, “Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy,” Cytokine Growth Factor Rev., 2003, 14:337-348.
Baetu and Hiscott, “On the TRAIL to apoptosis,” Cytokine Growth Factor Rev., 2002, 13:199-207.
Barbas and Lerner, “Combinatorial immunoglobulin libraries on the surface of phage (phabs): Rapid selection of antigen-specific Fabs,” Methods: A Companion to Methods in Enzymology, 1991, 2(2):119-124.
Baines and Thorpe, “Purification of Immunoglobulin G (IgG),” Meth. Mol. Biol., 1992, 10:79-104.
Carter et al., “Humanization of an anti-p185HER2 antibody for human cancer therapy,” Proc. Natl. Acad. Sci. USA, 1992, 89:4285-4289.
Coligan et al., “Production of Polyclonal Antisera in Rabbits, Rats, Mice and Hamsters,” Current Protocols in Immunology, 1992, section 2.4.1.
Cretney et al., “TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer,” Immunol Cell Biol, 2006, 84:87-98.
Edelman et al., “Hydrolysis with Pepsin,” Meth. Enzymol., 1967, 1:422.
Emery et al., “Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL,” J. Biol. Chem., 1998, 273:14363-14377.
Green et al., “Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs,” Nature Genet., 1994, 7:13-21.
Green et al., “Production of Polyclonal Antisera,” Immunochemical Protocols, 1992, 10:1-5, Manson (ed.), Humana Press.
Held and Schulze-Osthoff, “Potential and caveats of TRAIL in cancer therapy,” Drug Resistance Updates, 2001, 4:243-252.
Holen et al., “Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells,” Cancer Res., 2002, 62:1619-1623.
Hu et al., “Tumor Necrosis Factor-related Apoptosis-inducing Ligand Receptors Signal NF-κB and JNK Activation and Apoptosis through Distinct Pathways,” J Biol Chem, 1999, 274(43):30603-30610.
Hyrup et al., “Peptide Nucleic Acids (PNA): Synthesis, Properties and Potential Applications,” Bioorg. Med. Chem., 1996, 4:5-23.
Jones et al., “Replacing the complementarity-determining regions in a human antibody with those from a mouse,” Nature, 1986, 321(6069):522-525.
Köhler and Milstein, “Continuous cultures of fused cells secreting antibody of predefined specificity,” Nature, 1975, 256:495-497.
Krieg et al., “Trail-β and Trail-γ: two novel splice variants of the human TNF-related apoptosis-inducing ligand (TRAIL) without apoptotic potential,” Br J Cancer, 2003, 88(6):918-927.
Leblanc and Ashkenazi, “Apo2L/TRAIL and its death and decoy receptors,” Cell Death Differ, 2003, 10:66-75.
Lonberg et al., “Antigen-specific human antibodies from mice comprising four distinct genetic modifications,” Nature, 1994, 368(6474):856-859.
Losman et al., “Baboon anti-idiotype antibodies mimic a carcinoembryonic antigen epitope,” Int. J. Cancer, 1990, 46 (2):310-314.
Lum et al., “Induction of Cell Death in Human Immunodeficiency Virus-Infected Macrophages and Resting Memory CD4 T Cells by TRAIL/Apo2L,” J. Virol., 2001, 75(22):11128-11136.
Malhi and Gores, “TRAIL resistance results in cancer progression: a TRAIL to perdition?” Oncogene, 2006, 25 (56):7333-7335.
Nisonoff et al., “Separation of univalent fragments from the bivalent rabbit antibody molecule by reduction of disulfide bonds,” Arch. Biochem. Biophys., 1960, 89:230-244.
Orlandi et al., “Cloning immunoglobulin variable domains for expression by the polymerase chain reaction,” Proc. Natl. Acad. Sci. USA, 1989, 86:3833-3837.
Porter, “The hydrolysis of rabbit g-globulin and antibodies with crystalline papain,” Biochem. J., 1959, 73:119-127.
Riechmann et al., “Reshaping human antibodies for therapy,” Nature, 1988, 332:323-327.
Sambrook et al., Molecular Cloning, second edition, sections 7.39-7.52 Cold Spring harbor Laboratory, Plainview, NY.
Sandhu, “Protein engineering of antibodies,” Crit. Rev. Biotech., 1992, 12(5-6):437-462.
Singer et al., “Optimal humanization of 1B4, an anti-CD18 murine monoclonal antibody, is achieved by correct choice of human V-region framework sequences,” J. Immunol., 1993, 150:2844-2857.
Summerton and Weller, “Morpholino antisense oligomers: design, preparation, and properties,” Antisense Nucleic Acid Drug Dev., 1997, 7:187-195.
Taylor et al., “Human immunoglobulin transgenes undergo rearrangement, somatic mutation and class switching in mice that lack endogenous IgM,” Int. Immunol., 1994, 6(4):579-591.
Van Loon and Weinshilboum, “Thiopurine methyltransferase isozymes in human renal tissue,” Drug Metab. Dispos., 1990, 18:632-638.
Van Loon et al., “Human kidney thiopurine methyltransferase: Photoaffinity labeling with S-adenosyl-L-methionine,” Biochem Pharmacol., 1992, 44:775-785.
Verhoeyen et al., “Reshaping human antibodies: grafting an antilysozyme activity,” Science, 1988, 239:1534-1536.
Vlahakis et al., “Human Immunodeficiency Virus-Induced Apoptosis of Human Hepatocytes via CXCR4,” J. Infect. Dis., 2003, 188(10):1455-1460.
Wang and El-Deiry, “Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy,” Proc Natl Acad Sci USA, 2003, 100(25):15095-15100.
Winter et al., “Making antibodies by phage display technology,” Ann. Rev. Immunol., 1994, 12:433-455.
Wong et al., “Human GM-CSF: molecular cloning of the complementary DNA and purification of the natural and recombinant proteins,” Science, 1985, 228:810-815.
International Search Report/Written Opinion in PCT/US2007/75115 mailed Sep. 30, 2008, 12 pages.
International Preliminary Report on Patentability in PCT/US2007/75115 mailed Feb. 10, 2009, 8 pages.
Wang and El-Deiry, “TRAIL and apoptosis induction by TNF-family death receptors,” Oncogene, 2003, 22:8628-8633.
Badley Andrew D.
Bren Gary D.
Schnepple David J.
Fish & Richardson P.C.
Kaufman Claire
Mayo Foundation for Medical Education and Research
Spector Lorraine
LandOfFree
Methods of reducing trail-induced apoptosis by trail isoforms does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of reducing trail-induced apoptosis by trail isoforms, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of reducing trail-induced apoptosis by trail isoforms will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2678217